Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Nektar Therapeutics (NKTR) Tops Q4 EPS by 3c
February 25, 2021 5:53 PM ESTNektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.65), $0.03 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $30.01 million.
"This past year, Nektar made significant progress advancing our clinical pipeline of novel... More
